Stephan Stilgenbauer, MD PhD¹, Osman Ilhan^2*, Darius Woszczyk^3*, Christoph Renner^4*, Eva Mikuskova^5*, Sebastian Böttcher, MD^6*, Eugen Tausch, MD^7*, Tom Moore^8*, Nicola Tyson^9*, Helena Adamis^8*, Véronique Leblonde^10*, Francesc Bosch¹¹ and Robin Foà^12*

¹University of Ulm, Ulm, Germany
²Ankara University, Ankara, Turkey
³State Hospital, Opole, Poland
⁴OnkoZentrum Zurich, Zurich, Switzerland
⁵National Cancer Institute, Bratislava, Slovakia
⁶Campus Kiel, University Hospital of Schleswig-Holstein, Kiel, Germany
⁷Department of Internal Medicine III, Ulm University Medical Center, Ulm, Germany
⁸F. Hoffmann-La Roche Ltd, Basel, Switzerland
⁹Roche Products Ltd, Welwyn, United Kingdom
¹⁰UPMC GRC11-GRECHY AP-HP Hôpital Pitié Salpêtrière, Paris, France
¹¹Hospital Vall d'Hebron, Barcelona, Spain
¹²Hematology, Department of Cellular Biotechnologies and Hematology, “Sapienza” University, Rome, Italy

Ian W. Flinn, MD, PhD¹, Mark Brunvand, MD², Michael Y. Choi, M.D.³, Martin J.S. Dyer, Prof.⁴, John Gribben, MD, DSc⁵, Peter Hillmen, MB, ChB, PhD⁶, Jeffrey Jones, MD, MPH⁷, Yan Li^8*, Mehrdad Mobasher, MD⁸, Gregory Vosganian^8* and Thomas J. Kipps, M.D., PhD.³

¹Hematologic Malignancies Research Program, Sarah Cannon Research Institute, Nashville, TN
²Colorado Blood Cancer Institute, Denver, CO
³University of California School of Medicine, San Diego, CA
⁴Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, United Kingdom
⁵Barts Cancer Center, The London School of Medicine, London, United Kingdom
⁶St. James University Hospital, Leeds, United Kingdom
⁷Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
⁸Genentech, Inc., South San Francisco, CA

Alessandra Tedeschi, MD^1*, Paul M. Barr, MD², Tadeusz Robak, MD, PhD³, Carolyn Owen, MD^4*, Paolo Ghia, MD, PhD⁵, Osnat Bairey, MD^6*, Peter Hillmen, MB, ChB, PhD⁷, Nancy L Bartlett, MD⁸, Jianyong Li, MD⁹, David Simpson, MBBS¹⁰, Sebastian Grosicki, MD, PhD¹¹, Stephen Devereux, FRCP, FRCPath, PhD¹², Helen McCarthy, FRCP, FRCPath, PhD^13*, Steven Coutre, MD¹⁴, Hang Quach, MD^15*, Gianluca Gaidano, MD, PhD¹⁶, Zvenyslava Maslyak, MD^17*, Don A. Stevens, MD¹⁸, Ann Janssens, MD^19*, Fritz Offner, MD, PhD²⁰, Jiří Mayer, MD²¹, Michael O'Dwyer, MD²², Andrzej Hellmann, MD, PhD²³, Anna Schuh, MD, PhD^24*, Tanya Siddiqi, MD²⁵, Aaron Polliack, MD^26*, Constantine S. Tam, MBBS²⁷, Michael Keating, MBBS²⁸, Deepali Suri, MS^29*, Cathy Zhou, MS^29*, Fong Clow, ScD²⁹, Lori Styles, MD^29*, Danelle F. James, MD, MAS^29*, Thomas J. Kipps, M.D., PhD.³⁰ and Jan A. Burger, MD, PhD²⁸

¹Azienda Ospedaliera Niguarda Cà Granda, Milano, Italy
²University of Rochester, Rochester, NY
³Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
⁴Tom Baker Cancer Centre, Calgary, AB, Canada
⁵Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milano, Italy
⁶Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
⁷The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, United Kingdom
⁸Washington University School of Medicine, Saint Louis, MO
⁹Jiangsu Province Hospital, Nanjing, China
¹⁰North Shore Hospital, Auckland, New Zealand
¹¹Department of Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice, Poland
¹²Kings College Hospital, London, United Kingdom
¹³Royal Bournemouth Hospital, Bournemouth, United Kingdom
¹⁴Department of Medicine, Stanford University School of Medicine, Stanford, CA
¹⁵St. Vincent's Hospital, University of Melbourne, Melbourne, Australia
¹⁶Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
¹⁷Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine, Lviv, Ukraine
¹⁸Norton Cancer Institute, Louisville, KY
¹⁹University Hospital Leuven, Leuven, Belgium
²⁰University Hospital Gent, Gent, Belgium
²¹Fakultni Nemocnice Brno, Brno, Czech Republic
²²University College Hospital Galway, Galway, Ireland
²³Department of Hematology, University Clinical Center of Medical University of Gdańsk, Gdańsk, Poland
²⁴University of Oxford, Oxford, United Kingdom
²⁵City of Hope National Medical Center, Duarte, CA
²⁶Hadassah University Hospital, Hebrew University Medical School, Jerusalem, Israel
²⁷Peter MacCallum Cancer Centre and St. Vincent's Hospital, East Melbourne, Australia
²⁸The University of Texas MD Anderson Cancer Center, Houston, TX
²⁹Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
³⁰University of California San Diego, Moores Cancer Center, La Jolla, CA

Kirsten Fischer, MD^1*, Anna-Maria Fink, MD^1*, Helen Bishop^2*, Mark Dixon^2*, Jasmin Bahlo^1*, Michael Y. Choi, M.D.³, Robert Weinkove, MD, PhD⁴, K. Sue Robinson, MD⁵, Martin Dreyling, MD, PhD^6*, Till Seiler, MD^6*, Stephen Opat, MD⁷, Carolyn Owen, MD^8*, Javier Lopez Sr., MD, PhD^9*, Nadine Kutsch, MD^1*, Eugen Tausch, MD^10*, Matthias Ritgen, MD^11*, Rod A. Humerickhouse, MD, PhD¹², Kathryn Humphrey^2*, Michael K. Wenger, MD¹³, Valentin Goede, MD^1,14*, Barbara Eichhorst, MD¹, Clemens-Martin Wendtner, MD^1,15, Stephan Stilgenbauer, MD¹⁶, Thomas J. Kipps, MD, PhD¹⁷ and Michael Hallek, MD¹

¹Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany
²F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom
³University of California, San Diego, La Jolla, CA
⁴Malaghan Institute of Medical Research, Wellington, New Zealand
⁵Queen Elizabeth II Health Science Center, Halifax, Canada
⁶Department of Internal Medicine III, University Hospital LMU Munich, Munich, Germany
⁷Monash Haematology, Monash University, Clayton, Victoria, Australia
⁸Tom Baker Cancer Centre, Calgary, AB, Canada
⁹Department of Hematology, Hospital Ramon y Cajal, Madrid, Spain
¹⁰Department of Internal Medicine III, Ulm University Medical Center, Ulm, Germany
¹¹Second Department of Internal Medicine, University of Kiel, Kiel, Germany
¹²AbbVie Inc., North Chicago, IL
¹³F. Hoffmann-La Roche Ltd, Basel, Switzerland
¹⁴German CLL Study Group, Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany
¹⁵Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany
¹⁶Department of Internal Medicine III, Ulm University, Ulm, Germany
¹⁷Moores Cancer Center, University of California, San Diego, San Diego, CA

Benjamin L Lampson, MD, PhD^1*, Tiago Matos, MD, MSc^2*, Haesook T. Kim, PhD^3*, Siddha Kasar, PhD^1*, Elizabeth A. Morgan, MD⁴, Masahiro Hirakawa, MD, PhD^2*, Joshua Fein^1*, Stacey M. Fernandes^1*, Jerome Ritz, MD^1,5 and Jennifer R. Brown, MD, PhD⁶

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Division of Hematologic Malignancies, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
³Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
⁴Department of Pathology, Brigham and Women's Hospital, Boston, MA
⁵Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA
⁶Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

Stefano Molica, MD¹, Diana Giannarelli, MD^2*, Luciano Levato, MD^3*, Rosanna Mirabelli, MD^4*, Massimo Gentile, MD^5* and Fortunato Morabito, MD^6*

¹Oncology/Hematology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy
²Biostatistic Unit, IRCCS Regina Elena, Rome, Italy
³Department Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy
⁴Department Hematology-Oncology, Catanzaro, Italy
⁵U.O.C. di Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy
⁶Section of Hematology, A.O. L'Annunziata of Cosenza, Cosenza, Italy